Professor of Medicine
Gastroenterology
Dr. William M. Grady, MD
|
|
Give Review
William Grady practices Gastroenterology. He studied medicine at University of Michigan Medical School. He received 2 awards: "Elected Member" and "Fellow (AGAF)". Dr. William M. Grady is also a published doctor. He has 98 paper published. The most recent paper is: Incidence of neoplastic polyps in ileal pouch of patients with familial adenomatous polyposis after restorative proctocolectomy.
Publications
- Methylated B3GAT2 and ZNF793 Are Potential Detection Biomarkers for Barrett's Esophagus.
- Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers.
- Actionable exomic incidental findings in 6503 participants: challenges of variant classification.
- Molecular markers predictive of chemotherapy response in Colorectal cancer.
- The Molecular Pathogenesis of Colorectal Cancer and Its Potential Application to Colorectal Cancer Screening.
- Comparative effectiveness of next generation genomic sequencing for disease diagnosis: Design of a randomized controlled trial in patients with Colorectal cancer/polyp...
- Characterisation of Familial Colorectal Cancer Type X, Lynch syndrome, and non-familial Colorectal cancer.
- CpG Island Methylator Phenotype is Associated With Response to Adjuvant Irinotecan-Based Therapy for Stage 3 Colon Cancer.
- Barrett's Esophagus Translational Research Network (BETRNet): The Pivotal Role of Multi-institutional Collaboration in Esophageal Adenocarcinoma Research.
- Differences in DNA Methylation Signatures Reveal Multiple Pathways of Progression from Adenoma to Colorectal Cancer.
- Selective detection of target proteins by Peptide-enabled graphene biosensor.
- Biosensors: selective detection of target proteins by Peptide-enabled graphene biosensor (small 8/2014).
- Epigenetic biomarkers in esophageal Cancer.
- Patterns of DNA methylation in the normal colon vary by anatomical location, gender, and age.
- Molecular Alterations and Biomarkers in Colorectal Cancer.
- GRG Update: DDW 2013.
- Altered RECQ Helicase Expression in Sporadic Primary Colorectal Cancers.
- NTRK3 Is a Potential Tumor Suppressor Gene Commonly Inactivated by Epigenetic Mechanisms in Colorectal Cancer.
- Inactivation of TGF-? signaling and loss of PTEN cooperate to induce colon Cancer in vivo.
- Genomic Aberrations Occurring in Subsets of Serrated Colorectal Lesions but not Conventional Adenomas.
- RET is a potential tumor suppressor gene in Colorectal cancer.
- Context is everything for dependence receptors in Colorectal cancer.
- Colorectal Endoscopy, Advanced Adenomas, and Sessile Serrated Polyps: Implications for Proximal Colon Cancer.
- Fbw7 and p53 cooperatively suppress advanced and chromosomally unstable intestinal Cancer.
- Variation in Age at Cancer Diagnosis in Familial versus Nonfamilial Barrett's Esophagus.
- Aberrantly methylated PKP1 in the progression of Barrett's Esophagus to esophageal adenocarcinoma.
- DNA methylation profiling in Barrett's Esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses.
- Epigenetics and Colorectal cancer.
- Association of insulin and insulin-like growth factors with Barrett's oEsophagus.
- TGF-? signaling promotes hepatocarcinogenesis induced by p53 loss.
- Quality assessment and correlation of microsatellite instability and immunohistochemical markers among population- and clinic-based Colorectal tumors results from the ...
- Epigenomic Analysis of Aberrantly Methylated Genes in Colorectal Cancer Identifies Genes Commonly Affected by Epigenetic Alterations.
- Linking epidemiology to epigenomics--where are we today?
- TGF-beta inactivation and TGF-alpha overexpression cooperate in an in vivo mouse model to induce hepatocellular carcinoma that recapitulates molecular features of huma...
- A segregation analysis of Barrett's Esophagus and associated adenocarcinomas.
- Aberrant DNA methylation occurs in colon Neoplasms arising in the azoxymethane colon cancer model.
- Assessment of familiality, obesity, and other risk factors for early age of cancer diagnosis in adenocarcinomas of the Esophagus and gastroesophageal junction.
- Comparative analysis of PCR-based biomarker assay methods for Colorectal polyp detection from fecal DNA.
- TGF-beta receptor inactivation and mutant Kras induce intestinal Neoplasms in mice via a beta-catenin-independent pathway.
- Genomic and epigenetic instability in Colorectal cancer pathogenesis.
- The aberrant methylation of TSP1 suppresses TGF-beta1 activation in Colorectal cancer.
- Mutational inactivation of TGFBR2 in microsatellite unstable colon Cancer arises from the cooperation of genomic instability and the clonal outgrowth of transforming g...
- Making the case for DCC and UNC5C as tumor-suppressor genes in the colon.
- Tumor Paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci.
- Consortium approach to identifying genes for Barrett's Esophagus and esophageal adenocarcinoma.
- Evidence for the role of aberrant DNA methylation in the pathogenesis of Lynch Syndrome adenomas.
- Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic Neoplasms and invasive adenocarcinoma of the pancreas.
- Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal Neoplasms initiated by Apc mutation.
- Familiality in Barrett's Esophagus, adenocarcinoma of the Esophagus, and adenocarcinoma of the gastroesophageal junction.
- CpG island methylation of genes accumulates during the adenoma progression step of the multistep pathogenesis of Colorectal cancer.
- Do adverse histopathologic findings in Colorectal cancer patients explain disparate outcomes?
- Proliferation and Cdk4 expression in microsatellite unstable colon Cancers with TGFBR2 mutations.
- Keratin 19 gene drives Cre recombinase expression throughout the early postimplantation mouse embryo.
- Transforming growth factor-beta, Smads, and Cancer.
- Ionizing radiation and rectal Cancer: victims of our own success.
- Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with Colorectal polyps.
- Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon Cancer.
- Surveillance and Treatment of Periampullary and Duodenal Adenomas in Familial Adenomatous Polyposis.
- Genomic instability and colon Cancer.
- GISTs: the revolution continues.
- Diagnosis and management of hereditary non-polyposis colon Cancer.
- Genetic testing for high-risk colon Cancer patients.
- Hereditary colon Cancer genes.
- Hereditary diffuse gastric Cancer: more answers or more questions?
- Genetic and epigenetic alterations in colon Cancer.
- Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate Cancer.
- Influence of appropriate lower extremity orthotic management on ambulation, Pain, and fatigue in a postpolio population.
- Incidence of neoplastic polyps in ileal pouch of patients with familial adenomatous polyposis after restorative proctocolectomy.
- Gastric Cancer: new genetic developments.
- What's new with RII?
- Hereditary diffuse gastric Cancer: diagnosis, genetic counseling, and prophylactic total gastrectomy.
- Reconstitution of TGF-beta sensitivity in the VACO-411 human colon carcinoma line by somatic cell fusion with MCF-7.
- E-cadherin mutation-based genetic counseling and hereditary diffuse Gastric carcinoma.
- Gastroesophageal reflux symptoms in patients with adenocarcinoma of the Esophagus or cardia.
- Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric Cancer.
- p27 cell-cycle inhibitor is inversely correlated with lymph node metastases in right-sided colon Cancer.
- E-cadherin germline mutations define an inherited Cancer syndrome dominated by diffuse gastric Cancer.
- Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon Cancers.
- Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas.
- Mini-microabscess Syndrome in liver transplant recipients.
- Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon Cancer.
- Demographic and phenotypic features of 70 families segregating Barrett's oEsophagus and oesophageal adenocarcinoma.
- Inactivation of TGF-beta signaling in hepatocytes results in an increased proliferative Response after partial hepatectomy.
- Molecular basis for subdividing hereditary colon Cancer?
- Promoter methylation status of the MGMT, hMLH1, and CDKN2A/p16 genes in non-neoplastic mucosa of patients with and without Colorectal adenomas.
- Genomic instability and Colorectal cancer.
- Epigenetic events in the colorectum and in colon Cancer.
- DNA alkylation and DNA methylation: cooperating mechanisms driving the formation of Colorectal adenomas and adenocarcinomas?
- CIMP and colon Cancer gets more complicated.
- Colorectal cancer molecular biology moves into clinical practice.
- Use of folic acid-containing supplements after a diagnosis of Colorectal cancer in the Colon Cancer Family Registry.
- The next thing in prognostic molecular markers: microRNA signatures of Cancer.
- Insights into the role of DNA methylation in Disease through the use of mouse models.
- Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in Colorectal cancer.
- TGF-beta receptor levels regulate the specificity of signaling pathway activation and biological effects of TGF-beta.
- Mutation Detection inTGF-? Receptors.
- TGF-beta has paradoxical and context dependent effects on proliferation and anoikis in human Colorectal cancer cell lines.
Schools
University Of Michigan Medical School
University Wa
Case Western Reserve University
Procedures Preformed
- Colonoscopy, Proctosigmoidoscopy, and Sigmoidoscopy
- Endoscopy (Esophagus, Stomach, Small Intestine)
- Manometry
Conditions Treated
- Abdominal Pain
- Anemia
- Barrett's Esophagus
- Benign Neoplasm of the Digestive System
- View All
Doctors Specialties
- Gastroenterology
Accepted Insurances
Awards
- Elected Member
- Fellow (AGAF)
Education
-
Case Western Reserve University - University Hospitals -
University of Michigan Hospitals and Health Centers -
University of Washington -
University of Michigan Medical School
Hospital
-
University of Washington Medical Center
Drug Facts
| NPI NUMBER | 1407943822 | |
| NPPES Provider LastName | GRADY | |
| NPPES Provider FirstName | WILLIAM | |
| NPPES Provider ZIPCode | 981950001 | |
| NPPES Provider State | WA | |
| Specialty Description | Gastroenterology | |
| Total Claim Count | 201.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1407943822 |
| Last Name Of The Provider | GRADY |
| First Name Of The Provider | WILLIAM |
| View All |
Similar Doctors
|
Dr. Michael Gluck, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Adam W. Templeton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert L. Sanford, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anita Afzali, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas D. Amankonah, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James D. Lord, MD |
|
|
Dr. John M. Inadomi, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Matthew S. Cole, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pushpjeet S. Kanwar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen M. Vindigni, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gregory D. Lutzak, MD
This Doctor is OpenDoctor Recommended.
|